ALICIA
RODRIGUEZ GASCON
PROFESORADO CATEDRATICO/A DE UNIVERSIDAD
ANA DEL
POZO RODRIGUEZ
PROFESORADO TITULAR DE UNIVERSIDAD
Publicaciones en las que colabora con ANA DEL POZO RODRIGUEZ (48)
2024
-
Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review
Drug Delivery and Translational Research
2023
-
Expression of a conserved sequence of SARS-CoV-2 for panβ-coronavirus vaccine development
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease
Pharmaceutics, Vol. 15, Núm. 7
-
Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
Pharmaceutics, Vol. 15, Núm. 4
-
SLNs como sistemas de transfección para el desarrollo deterapias CAR-T ex vivo
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Terapia génica
Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 137-153
-
siRNA vectors based on golden lipid nanoparticles for Fabry Disease
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
2022
-
Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease
Nanomaterials, Vol. 12, Núm. 14
-
mRNA delivery technologies: Toward clinical translation
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293
2021
-
Functionalised SLNs-based nanovectors for gene therapy in Fabry disease: The liver as an α-Galactosidase A factory
RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 46-48
-
Mrna-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation
Pharmaceutics, Vol. 13, Núm. 9
-
Substrate reduction therapy based on siRNA for Fabry Disease
RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 84-86
-
α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
Pharmaceutics, Vol. 13, Núm. 6
2020
-
Gene Therapy
Advances in Biochemical Engineering/Biotechnology (Springer), pp. 321-368
-
Nanomedicines to deliver mRNA: State of the art and future perspectives
Nanomaterials, Vol. 10, Núm. 2
-
Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA
Molecules (Basel, Switzerland), Vol. 25, Núm. 24
2019
-
Gene-terapia: ikuspegi terapeutiko berria begietako gaitzen tratamenduan
Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 36, pp. 31-48
-
MMP-9 downregulation with lipid nanoparticles for inhibiting corneal neovascularization by gene silencing
Nanomaterials, Vol. 9, Núm. 4
2018
-
Nonviral delivery systems for gene therapy for retina and posterior segment disease
Drug Delivery for the Retina and Posterior Segment Disease (Springer International Publishing), pp. 131-149